All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

January 6th 2025

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

January 6th 2025

Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL

January 6th 2025

Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.

New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers

January 6th 2025

A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

January 6th 2025

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC

January 6th 2025

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

January 6th 2025

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

January 6th 2025

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

January 6th 2025

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Patient Factors Drive IO Combination Selection in Unresectable HCC

January 5th 2025

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

The OncFive: Top Oncology Articles for the Week of 12/29

January 4th 2025

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

January 4th 2025

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

Revisit Every OncLive On Air Episode From December 2024

January 3rd 2025

In case you missed any, read a recap of the episodes of OncLive On Air that aired in December 2024.

Survey Says: AI Isn’t Going Anywhere in Oncology, But Validity Concerns Remain

January 3rd 2025

Nearly half of oncologists use AI tools for document and communication/editing purposes in their practice, and most foresee an increase in AI integration.

Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC

January 3rd 2025

Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.

Roswell Park Team Discovers New Treatment Target for Neuroendocrine Prostate Cancer

January 3rd 2025

Data published in Oncogene suggest that the mitochondrial unfolded protein response could be an Achilles’ heel for neuroendocrine prostate cancer.

Satri-Cel Improves PFS in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer

January 3rd 2025

Satri-cel improved PFS vs investigator’s choice of therapy in pretreated CLDN18.2-positive advanced gastric/GEJ cancer.

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC

January 3rd 2025

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

A Continuous Race of Biomarker Research and Molecular Strategies

January 3rd 2025

Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

January 3rd 2025

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.